Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma

Meng, Yuqi; Cao, Xun; Wen, Zhesheng; Liu, Q. W.; Tan, Zheng; Duan, Hao; Ma, G. W.; Lin, Peng

doi:10.1111/dote.12128

Cited by 8 publications

(3 citation statements)

References 34 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, recent epidemiologic studies even suggest that elevated circulating levels of SAA, not only merely mark the presence of prevalent carcinoma, but also should possibly be related to an increased risk of future cancer in apparently healthy individuals (Sasazuki et al, 2010;Shiels et al, 2013). Most importantly, several researches have confirmed that SAA turned out to be an independent and effective factor in predicting survival of patients with different tumors (Kimura et al, 2001;Chan et al, 2007;Meng et al, 2014).…”

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 99%

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Ni¹,

Ye²,

Fu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the prognostic value of serum amyloid A (SAA) in patients with hepatocellular carcinoma (HCC) undergoing surgery. Materials and Methods: Preoperative serum samples of 328 patients with HCC who underwent curative resection and of 47 patients with benign liver lesion were assayed. Serum levels of SAA were measured by enzyme-linked immunosorbent assay and its correlations with clinicopathological characteristics and survival were explored. Results: Levels of SAA were significantly higher in patients with HCC than those with benign liver lesion. There were strong correlations between preoperative serum SAA level and tumor size and more advanced BCLC stage. On univariate analysis, elevated SAA was associated with reduced disease-free survival and overall survival (p=0.001 and 0.03, respectively). Multivariate analyses showed that serum SAA level was an independent prognostic factor for overall survival (hazard ratio 2.80, p=0.01). Conclusions: High SAA serum level is a novel biomarker for the prognosis of HCC patients.

show abstract

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 99%

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Ni¹,

Ye²,

Fu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…A recent investigation demonstrated that SAA outperformed CRP in terms of prognostic accuracy for predicting 90-day mortality, overall survival and unfavorable outcomes in patients with intracerebral hemorrhage [ 34 ]. Similarly, a retrospective cohort study revealed that preoperative SAA levels exhibited superior predictive performance compared to CRP in determining overall survival among patients with esophageal squamous cell carcinoma [ 35 ]. These data suggests that SAA may serve as a more reliable prognostic indicator for various diseases, although our analysis did not reveal clear superiority of SAA over CRP.…”

Section: Discussionmentioning

confidence: 99%

Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis

Li,

Liu,

Zhang

et al. 2023

Renal Failure

View full text Add to dashboard Cite

Backgrounds The available literature on the correlation between serum amyloid A (SAA) and prognosis of chronic kidney disease (CKD) are limited, and the findings from existing studies are inconclusive. This meta-analysis aimed to evaluate the available evidence regarding the link between SAA and risks of all-cause and cardiovascular mortality in CKD patients. Additionally, we aimed to investigate the potential dose-response relationships, provided that adequate data is accessible. Methods Pubmed and Embase were searched for related literature (last update: 12 July 2023). The pooled effect estimates were calculated using random- or fixed-effects models depending on heterogeneity among studies. Results This meta-analysis incorporated 8 studies encompassing 2331 CKD patients. The findings revealed an 85% increase in all-cause mortality risk [hazard risk (HR) 1.85, 95% confidence interval (CI) 1.29–2.65] and a 39% increase in cardiovascular mortality risk (HR 1.07, 95% CI 1.07–1.80) when comparing the highest tertile of baseline SAA levels to the lowest tertile. Furthermore, a positive linear relationship between SAA and all-cause mortality risk was observed ( P non-linearity = 0.959), with a 17.7% increase in risk for each 10 mg/L SAA increase (HR 1.177, 95% CI 1.055–1.313). Similarly, a linear relationship between SAA and cardiovascular mortality risk was identified ( P non-linearity = 0.477) with a 19.3% increase in risk for each 10 mg/L SAA increase (HR 1.193, 95% CI 1.025–1.388). Conclusions This meta-analysis provided evidence that SAA levels are positively and linearly associated with risks of all-cause and cardiovascular mortality among CKD patients.

show abstract

“…However, the role of tumor markers in early detection is severely limited because of their unsatisfactory sensitivities . Even TNM staging has limited roles in predicting survival, because outcomes may differ dramatically for patients within the same clinical stage . Thus, new biomarkers are required to predict patient survival and to select the patients who will benefit from specific treatments such as adjuvant therapies.…”

Section: Introductionmentioning

confidence: 99%

Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus

et al. 2015

View full text Add to dashboard Cite

Summary Despite improvements in surgical techniques, perioperative management, and multidisciplinary therapy, treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) remain poor. Therefore, development of novel molecular biomarkers, which either predict patient survival or become therapeutic targets, is urgently required. In the present study, to facilitate early detection of ESCC and predict its clinical course, we investigated the relationship of the serum level of melanoma‐associated antigen (MAGE)‐D4 to patients' clinicopathological characteristics. Using quantitative real‐time reverse transcription‐polymerase chain reaction and enzyme‐linked immunosorbent assays, we determined the levels of MAGE‐D4 mRNA and protein in cell lysates and conditioned medium of cultures, respectively, of nine ESCC cell lines. Further, we determined MAGE‐D4 levels in serum samples collected from 44 patients with ESCC who underwent radical esophagectomy without neoadjuvant therapy as well as from 40 healthy volunteers. Samples of conditioned medium and cell lysates contained comparable levels of MAGE‐D4 that correlated closely with the levels of MAGE‐D4 mRNA. Preoperative MAGE‐D4 levels in the sera of 44 patients with ESCC, which varied from 0 to 2,354 pg/mL (314 ± 505 pg/mL, mean ± standard deviation), were significantly higher compared with those of healthy volunteers. By setting the cutoff at the highest value for healthy volunteers (50 pg/mL), the MAGE‐D4‐positive group of patients was more likely to have shorter disease‐specific and disease‐free survival compared with those of the MAGE‐D4‐negative group, although the differences were not statistically significant. Our results indicate that the elevation of preoperative serum MAGE‐D4 levels in some patients with ESCC was possibly caused by excess production of MAGE‐D4 by tumor cells followed by its release into the circulation. Clinical implications of serum MAGE‐D4 levels should be validated in a large population of patients with ESCC.

show abstract

Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma

Cited by 8 publications

References 34 publications

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis

Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus

Contact Info

Product

Resources

About